Citations

Clear

3138 citation(s) found for "Smith, AM".

A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).
Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Couban, Stephen, Thirman, Michael J. , Halvorson, Alese E. , Tallman, Martin S. , Appelbaum, Frederick R. , Stone, Richard M. , Robinson, Sue, Chang, Julie , Mandrekar, Sumithra J. , Byrd, John C. , Smith, Mitchell R. , Godwin, John E. , Fehniger, Todd A. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 7503-7503

10.1200/jco.2017.35.15_suppl.7503 Get It

7503 Background: Prior to use of novel targeted agents for CLL, debate existed regarding the best chemoimmunotherapy regimen to build upon in patients (pts) with non-del(11q) disease. The role of lenalidomide (L) was also not defined. CALGB 10404 was a randomized phase 2 study addressing these questions. Methods: Pts with untreated CLL requiring therapy were randomized to treatment with fludarabine + rituximab (FR), FR + 6 monthly consolidative treatments of L (5 mg days 1-21/28 x 1 then 10 mg days 1-21/28 x 5) (FR+L), or FR + cyclophosphamide (FCR). Based on pretreatment central interphase cytogenetic screening, pts with del(11q22.3) in at least 20% of cells were excluded from the primary analysis, testing whether 2-year progression-free survival (PFS) rate was improved in non-del(11q) pts within each arm. A target accrual of 103 non-del(11q) pts per arm provided at least 84% power to detect an increase in 2-year PFS rate from 60% to 73%; the critical value was 69% using a single stage design and type I error rate of 4%. Results: A total of 342 non-del(11q) CLL pts were randomized to treatment with FR (n = 123), FR+L (n = 109), or FCR (n = 110). Baseline characteristics were similar across arms. Two-year PFS rates with exact 90% CIs were 64% (57-71%) (FR), 71% (63-78%) (FR+L), and 74% (66-80%) (FCR). Median PFS was significantly shorter with FR compared to FR+L (p = 0.03) and FCR (p < 0.01): 43 (95% CI: 33-50), 66 (95% CI: 45-not reached), and 78 (95% CI: 58-not reached) months respectively. Median overall survival (OS) has not been reached for any arm. OS at 1, 2, and 3 years was similar across arms, although there was a plateau in OS with no events beyond 41 months in the FR+L arm, different from FR/FCR where events continued to occur. The most common adverse events were cytopenias and infections. Conclusions: FR+L and FCR met the protocol defined primary endpoint. FR+L extended PFS relative to FR and a plateau in survival differentiated this arm from the FR/FCR arms. Future studies comparing FR+L to FCR or incorporating L into other novel treatment regimens are justified. Support: U10CA180821, U10CA180882, Celgene. Clinical trial information: NCT00602459.
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman, Jessica K. , Perl, Alexander E. , Litzow, Mark R. , Hill, Jason E. , Liu, Charles , Ritchie, Ellen K. , Neubauer, Andreas , Bahceci, Erkut, Hill, Jason , Cortes, Jörge E. , Smith, Catherine C. , Larson, Richard A. , Strickland, Stephen Anthony , Wang, Eunice S. , Martinelli, Giovanni , Levis, Mark J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 7003-7003

10.1200/jco.2017.35.15_suppl.7003 Get It

7003 Background: Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase I/II study (NCT02014558), specifically at doses ≥80 mg/d. This exploratory analysis assessed molecular response to gilteritinib in a CHRYSALIS subpopulation. Methods: Molecular response was assessed from bone marrow aspirates obtained at baseline and at ≥1 additional time point from FLT3mut+ patients (≥18 y) treated with 120 or 200 mg/d gilteritinib. These doses were identified due to their ability to induce consistent, potent FLT3 inhibition and high clinical response rates. FLT3-ITD and total FLT3 were quantified by NGS to assess molecular response. A Cox regression model of overall survival (OS) by Kaplan-Meier estimation established a FLT3-ITD:total FLT3 ratio (ITD signal ratio) of 10−2as the threshold for improved survival. Results: Of 147 FLT3-ITDmut+ patients who received gilteritinib 120 or 200 mg/d, 80 were included in this analysis. Composite response rate for these 80 patients was 55%. During response, 20 patients (25%) had an ITD signal ratio of ≤10−2. Of these 20 patients, 18 had a ratio of ≤10−3 (major molecular response [MMR]) and 13 had a ratio of ≤10−4 (minimal residual disease [MRD] negative). Median time to achieve minimum signal ratio was 54 days. Elimination of morphologic leukemia was observed in 80% of patients with ITD signal ratios <10−2. Patients who had a signal ratio ≤10−2, MMR, or were MRD negative had significantly longer median OS than those who did not (Table). Conclusions: Molecular responses to gilteritinib in FLT3-ITDmut+ R/R AML correlated with clinical response and improved OS. This is the first demonstration of molecular response to a FLT3 inhibitor in AML. These data suggest ITD signal ratio may predict durable clinical benefit of gilteritinib. Clinical trial information: NCT02014558. [Table: see text]
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-pos
Moreno‐Aspitia, Alvaro , Holmes, Eileen , Jackisch, Christian , Boyle, Frances , Korde, Larissa A. , Fumagalli, Debora , Izquierdo, Miguel , McCullough, Ann E. , Láng, István, Smith, Ian E., Barrios, Carlos H. , Gelber, Richard D. , Baselga, José, Piccart, Martine , Azambuja, Evandro de , Hillman, David W. , Wolff, Antonio C. , Pritchard, Kathleen I. , Untch, Michael , Xu, Binghe

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 502-502

10.1200/jco.2017.35.15_suppl.502 Get It

502 Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial defined in Amendments 11&12. Methods: From June 2007 to July 2011, 8381 patients (pts) were randomised from 946 sites in 44 countries to receive either L+T, T→L, L, or T. In 2011, due to futility the L arm was closed and is not included in this analysis. The primary end point is disease-free survival (DFS). Secondary objectives include treatment comparisons with respect to overall survival (OS), time to recurrence (TTR), time to distant recurrence (TDR), cardiac and overall safety and tolerability. Primary analysis results of the study were published in JCO 2015 34:1034-1042. This updated analysis occurs at a 6.9 yrs median follow up (MFU). Results: All patients have reached 5-years of follow-up. 705 DFS events for L+T vs T have been observed. HR for DFS was 0.86 (95% CI, 0.74-1.00; 6-yr DFS%=85% vs 82%) for L+T vs T and 0.93 (95% CI, 0.81-1.08; 6-yr DFS%=84% vs 82%) for T→L vs. T. The 6-year OS was 93%, 92%, and 91% for L+T, T→L, and T, respectively. HR for OS was 0.86 (95% CI, 0.70-1.06) for L+T vs. T and 0.88 (95% CI, 0.71-1.08) for T→L vs. T. DFS differences for L+T vs. T were slightly higher for the hormone-receptor(ER)-negative [HR 0.80 (95% CI, 0.64-1.00; 6-yr DFS%=84% vs. 80%)] and the sequential chemotherapy [HR 0.83 (95% CI, 0.69-1.00; 6-yr DFS%=83% vs.79%)] subgroups. There were no differences in sites of first DFS events according to treatment arm for CNS, loco-regional, or distant recurrences. There were more AEs related to study treatment (L+T 93% vs T 64%). The incidence of primary cardiac end points was low: 1% for L+T, 0.5% for T→L and 0.9% for T. Conclusions: The HRs for this updated analysis are similar to those from the Primary Analysis and the event rate remains lower than anticipated (705 vs 850 planned). Cardiac toxicity remains low. This analysis suggests that HER2+/ER- tumors may have a different biology than HER2+/ER+ and may benefit more from dual HER2 blockade. Long-term follow up continues. Clinical trial information: NCT00490139.
Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Yeatman, Timothy J. , Tibshirani, Robert , Williams, Richard T. , Hartman, Anne‐Renee , Seiden, Michael V., Liu, Minetta C. , Klein, Eric A. , Hubbell, Earl , Aravanis, Alexander M. , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Smith, David A. B.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12021-12021

10.1200/jco.2018.36.15_suppl.12021 Get It

A pilot randomized sham-controlled trial of MC5-A scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN).
Razzak, A. Rab, Ensminger, Jennifer, Saiki, Catherine, Loprinzi, Charles L. , Smith, Thomas J. , Blackford, Amanda

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22206-e22206

10.1200/jco.2018.36.15_suppl.e22206 Get It

Nasal vestibulitis: An under-recognized and under-treated side effect of cancer treatment.
Smith, Deanne, Zahrieh, David M. , Jatoi, Aminah , Yang, Ping , Loprinzi, Charles L. , Goyal, Gaurav , Cathcart-Rake, Elizabeth

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22172-e22172

10.1200/jco.2018.36.15_suppl.e22172 Get It

Rose geranium in sesame oil nasal spray: A potential treatment for nasal vestibulitis?
Smith, Deanne, Zahrieh, David , Loprinzi, Charles L. , Cathcart-Rake, Elizabeth , Goyal, Gaurav

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22166-e22166

10.1200/jco.2018.36.15_suppl.e22166 Get It

Scrambler therapy for established chemotherapy-induced neuropathy: A randomized phase II trial.
Loprinzi, Charles L. , Majithia, Neil , Bendel, Markus A. , Beutler, Andreas S. , Strick, D. M., Tilburt, Jon C. , Le‐Rademacher, Jennifer , McMurray, Ryan P. , Lachance, Daniel Honore , Cheville, Andrea , Smith, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10016-10016

10.1200/jco.2018.36.15_suppl.10016 Get It

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).
Kotasek, Dusan , Borazanci, Erkut , Smith, Sheri , Shah, Ajit , Walker, Michael J. , Cullen, Michael, Gagnon, Suzanne , Borazanci, Erkut , Tebbutt, Niall C. , Borad, Mitesh J. , Cullen, Michael T.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16231-e16231

10.1200/jco.2018.36.15_suppl.e16231 Get It

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
Curti, Brendan D. , Smith, David C. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Kuzel, Timothy M. , Amore, Benny , Grilley‐Olson, Juneko E. , Goel, Sanjay , Gajewski, Thomas Frank , Markovic, Svetomir N. , Mehta, Amitkumar , Guerrero, Abraham, Wang, Zejing , Coveler, Andrew L.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2018.36.15_suppl.3093 Get It